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The antiviral and cytotoxic effects of ara-arahinoside 
monophosphate, 2’,3’, dideoxy-cytidine, ganciclovir, 
9-2(-phosphonyhnethoxyethyl) adenine, 2’,3’dide- 
oxy3’-thiacytidine and recombinant interferon-alpha 
were studied using two human hepatitis B virus trans- 
fected hepatoma cell lines, HepGZ 2.2.15 and HB 
611. After 9 days of exposure, starting on day 3 after 
seeding, inhibition of extracellular HBV-DNA ex- 
pressed as IDss was in the 0.1-1.0 /cM range for 2’,3’- 
dideoxy3’-thiacytidine and 9-Z(-phosphonyhuethoxy- 
ethyl) adenine and >lO PM for dideoxy-cytidine, ara- 
arabinoside monophosphate and ganciclovir in both 
cell lines At 2.500 U/ml recombinant interferon-alpha 
showed less than 20% inhibition in both cell lines. The 
HBV-DNA inhibitory effects of 2’,3’dideoxy-3’-thia- 
cytidine and 9-2(-phosphonyhnethoxyethyl) adenine 
were also investigated after 1 and 3 days of exposure. 
In that setting IDsa’s were 10 and 3.3 PM for 2’,3’- 
dideoxy-3’-thiacytidine and >lOO and 30 PM for 9- 
2(-phosphonyhuethoxyethyl) adenine, respectively. No 
major inhibitory effect on hepatitis B surface antigen 
and hepatitis B e antigen secretion was observed for 
any agent in this study, except for 9-Z(-phosphonylme- 
thoxyethyl) adenine in HB 611 cells. Cytotoxicity 
ESEARCH R on hepatitis B virus has been hampered by the absence of an in vitro cell culture system 
for hepatitis B infection. Infection of hepatitis B virus 
in primary cultures of human hepatocytes has been re- 
ported, but great variability has been observed in levels 
of HBV replication (1). 
As an alternative, transfection of various hepatoma 
cell lines with hepatitis B virus DNA has been intro- 
duced. Stable transfection was established for the 
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measured by inhibition of [3H-methyl] deoxythymidi- 
ne incorporation and expressed as CDs,, on day 4 was 
in the 10-100 PM range for ara-arabinoside mono- 
phosphate; in the 100-1000 /IM range for 9-Z(-phos- 
phonylmethoxyethyl) adenine, ganciclovir and dide- 
oxy-cytidine; and >lOOO PM for 2’,3’-dideoxy-3’-thi- 
acytidine. This CDs0 decreased considerably (7-100 
fold) when measured on day 12 for dideoxy-cytidine, 
ganciclovir, 9-2(-phosphonyhuethoxyethyl) adenine 
and 2’,3’-dideoxy-3’-thiacytidine, but was similar for 
ara-arabinoside monophosphate. Since the order of 
antiviral HBV activity and cytotoxicity of nucleoside 
analogues was similar in the two transfected hepa- 
toma cell lines, we conclude that 2’,3’dideoxy-3’-thi- 
acytidine and 9-2(-phosphonylmethoxyethyl) adenine 
are very potent inhibitors of HBV-DNA, with a long- 
lasting effect. In view of the progressive toxicity with 
continuous administration, intermittent administra- 
tion might be an alternative mode of therapy. 
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HepG2 2.2.15 and the HB 611 cell lines. Both cell lines 
excrete hepatitis B surface antigen, hepatitis B e anti- 
gen and complete Dane particles (2,3). These two cell 
lines are now widely used as model systems for screen- 
ing of antiviral agents with activity against HBV In 
previous studies various experimental designs were de- 
scribed to assess the therapeutic effect of antiviral 
agents. Differences in time of start of exposure of cells 
to the agents, duration of exposure, cell system, time 
lapse between exposure and measurement of anti-HBV 
effect and different types of cytotoxicity tests may ulti- 
mately have influenced the results. Therefore, it is of 
interest to investigate the two commonly used HBV- 
producing cell lines, the HepG2 2.2.15 and the HB 611 
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cells, simultaneously For comparison of the feasibility 
of these cell lines, we have chosen antiviral agents with 
different inhibitory properties: ara-arabinoside mono- 
phosphate (Ara-AMP) (4) and ganciclovir (DHPG) as 
suspected DNA polymerase inhibitors (non-reactive in 
growth inhibit.ion of retroviruses: J. Bazarini, personal 
communication); 9-2(-phosphonylmethoxyethyl) aden- 
ine (PMEA) as inhibitor of DNA polymerase as well 
as reverse transcriptase (5), and dideoxy-cytidine (ddC) 
and 2’-3’-dideoxy-3’-thiacytidine (Lamivudine) as re- 
verse transcriptase inhibitors (6,7). Recombinant inter- 
feron-a (IFN-a) is a presumed inhibitor of the viral 
RNA and protein synthesis (8,9). It is very important 
to establish the effects of drug activity on cytotoxicity 
and the effect of cytotoxicity on the evaluation of the 
antiviral effect in the earliest phase of selection of new 
drugs. For this reason we investigated the time and 
duration of treatment in relation to antiviral effect and 
cytotoxicity. 
Material and Methods 
Antiviral agents 
Ara-arabinoside monophosphate and 2’3’-dideoxy cy- 
tidine were purchased from Sigma Chemical Co. (St 
Louis, USA). Ganciclovir was purchased from Sarva 
Syntex Corporation (Palo Alto, USA). Recombinant 
interferon-a was a gift from the Schering Plough Cor- 
poration (Kenilworth, NY, USA). 9-2-(phosphonyl- 
methoxyethyl) adenine was a gift from Dr. J. Balzarini 
(Rega Institute of the Catholic University, Leuven, Bel- 
gium). Lamivudine is the negative enantiomer of 2’,3’- 
dideoxy-3’-thiacytidine and was a gift from Glaxo Re- 
search and Development (Greenford, UK). 
Human hepatoma cell lines 
The HepG2 2.2.15 hepatoblastoma cell line was kindly 
donated by Dr. G. Acs (Mount Sinai Medical Center, 
New York, NY, USA); the HB 611 cell line was a gift 
from Dr. K. Matsubara (Institute of Molecular and 
Cellular Biology, Osaka, Japan). 
Cells were seeded onto 25 cm2 tissue culture flasks 
(Costar) at a density of 4~ lo4 cells/cm2 in Dulbecco’s 
modification of Eagle’s medium (DMEM), supple- 
mented with 2 mmol/l L-glutamine (Flow Labora- 
tories), garamycine (40 &ml), amphotericin B (2.5 pg/ 
ml), the neomycin analogue G418 (360 &ml for 
HepG2 2.2.15 cells; 200 &ml for HB 611 cells) and 
10% fetal bovine serum (FBS, Hyclone Laboratories 
Inc). When cells had reached confluence (day 6), FBS 
was reduced to 2%. Cell cultures were maintained in 
5% CO2 atmosphere at 37°C. 
All antiviral agents were investigated for their anti- 
HBV effects after continuous exposure of the cells to 
these drugs for 9 days. Initially, tenfold dilution steps 
were used. Intermediate dilution steps were chosen for 
the final experiments to obtain drug levels closer to the 
expected 50% inhibitory concentration. In these ex- 
periments exposure of the cells to the drug started on 
day 3 by replacing the culture medium with culture me- 
dium supplemented with the antiviral agent. This was 
repeated on day 6 and 9. 
In short-term exposure experiments, medium was 
also replaced on day 3 by culture medium containing 
the antiviral agent. Exposure of the cells to the drug 
ended after, respectively, 1 and 3 days. Medium with- 
out antiviral agent was changed on day 6 and 9. 
Cell culture supernatants from continuous (9 days) 
and short-(1 day and 3 days)-term exposures were har- 
vested on day 12 for HBV-DNA extraction. 
Analysis of HBV-DNA 
For analysis of extracellular HBV-DNA the cell culture 
supernatant was clarified by centrifugation at 1000 g 
for 10 min. Aliquots were stored at -20°C until further 
analysis. After concentration by polyethylene glycol 
(PEG, 10% w/v) precipitation, the pellets were resus- 
pended in a buffer consisting of 10 mM Tris-HCl pH 
8.2, 400 mM NaCl, 2 mM Na2EDTA, 0.6 mg/ml pro- 
teinase K and 1% SDS and incubated overnight at 
45°C. Total HBV-DNA was extracted with phenol, fol- 
lowed by extraction with phenol:chloroform:isoamyl 
alcohol (25:24: 1) and chloroform:isoamyl alcohol 
(24:l). The DNA was precipitated overnight in etha- 
nol. After two washes with ethanol 70%, the DNA pel- 
lets were dissolved in TE (10 mM Tris-HCl pH 7.5, 2 
mM Na2EDTA) in 10% of the starting volume. 
For dot blot analysis, extracted DNA was applied to 
a Hybond N+ membrane (Amersham Life Science 
Products) in the Convertible Filtration Manifold Sys- 
tem (BRL, Life Technologies Inc.) as described pre- 
viously (10). Three reference samples were included in 
any hybridization run for quality and sensitivity control. 
Hybridization of HBV-DNA sequences was per- 
formed with a [32P]dCTP labelled EcoRl fragment of 
pCPl0 containing the full length 3.2 kb genome of 
HBV All labelling reactions were carried out with the 
Prime-a-Gene Labelling System (Promega). HBV- 
DNA was visualized by autoradiography. The limit of 
detection was 0.1 pg HBV-DNA. 
The intensity of the autoradiographic dot spots was 
quantitated by scanning in an LKB 222-020 Ultra Scan 
XL laser densitometer. The 50% inhibitory dose (ID& 
was defined as the drug concentration that reduced the 
level of HBV-DNA in the culture medium by 50%. The 
IDs0 values were obtained by plotting percentage inhi- 
bition compared with control (no drug) versus the drug 
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In vitro anti-HBV effects in time 
TABLE 1 
Inhibitory effects of antiviral agents in HepG2 2.2.15 and HB 611 cells 
Anti-viral IDS,, +M) day 12 CD50 01M) TI50 W) 
agent HB 611 HepG 2.2.15 HB611 HepG2 2.2.15 HB 611 HepG2 2.2.15 
day 4 day 12 day 4 day 12 day 4 day 12 day 4 day 12 
A B C D E F CIA D/A E/B FIB 
Lamivudine 0.04 0.02 2800 150 3000 450 >lOOO >lOOO >lOOO >lOOO 
PMEA 0.70 1.20 150 20 150 20 214 10 516 21 
ddC 10 50 >500 40 >500 4 >50 4 >lO 0.08 
AraAMP 40 100 10 30 20 25 0.25 0.33 0.20 0.25 
DHPG >lOO’ >1002 180 20 430 25 cl.80 co.20 <4.30 co.20 
IFN-a U/ml >25003 >25004 >2500 >2500 >2500 >2500 _ _ _ 
1 At 100 PM; 44% Inhibition. 
* At 100 PM; 20% Inhibition. 
3 At 2500 U/ml; 10% Inhibition. 
4 At 2500 U/ml; 17% Inhibition. 
concentration. The IDso could be determined with a 
15% coefficient of variation. 
Cytotoxicity 
The 50% cytotoxic dose (CDs,,) was determined by in- 
hibition of [3H-methyl]deoxythymidine ([3H-methyl] 
dThd) incorporation and measured after 24 h of in- 
cubation at respectively 3 and 12 days after seeding 
(11). 
The Therapeutic Index (TI) is the ratio of CDS0 over 
ID5o. 
Extracellular HBsAg and HBeAg analysis 
HBsAg and HBeAg secretion in clarified tissue culture 
medium were analyzed on day 12. HBsAg and HBeAg 
were determined semi-quantitatively by end-point ti- 
tration in radioimmunoassays (AUSRIA II and HBe 
rDNA, Abbott Laboratories, Chicago, Ill., USA). 
Results 
Anti-HBV effect 
The inhibitory effect on the level of HBV-DNA in 
tissue culture medium from HepG2 2.2.15 and HB 611 
cells was determined on day 12. The level of HBV- 
DNA in supernatants of HB 611 cells not incubated 
with drugs resulted in weak signals after hybridization. 
Therefore Dane particle concentration by polyethy- 
leneglycol (PEG) preceded HBV-DNA extraction and 
dot blot hybridization. For comparison, PEG precip- 
itation was also applied to tissue culture medium of 
HepG2 2.2.15 cells. 
The order of effectiveness in HepG2 2.2.15 cells, 
based on 50% inhibition of HBV replication, was: La- 
mivudine, PMEA, ddC, Ara-AMP, DHPG and inter- 
feron-a. The same order was obtained for HB 611 cells 
(Table 1). The 50% inhibitory dose ranged from about 
0.02 PM for Lamivudine to > 100 PM for DHPG. For 
IFN-a only minimal inhibition was observed (10 and 
17% at 2500 U/ml for HB 611 and HepG2 2.2.15, re- 
spectively). 
Inhibition of extra-cellular HBsAg and HBeAg 
HBsAg and HBeAg secretion from both HepG2 2.2.15 
and HB 611 cell cultures were not inhibited for 
the antiviral agents under study except for PMEA, 
which inhibited HBsAg secretion in HB 611 cell cul- 
tures. A reproducible 50% inhibition was found at 
30 PM. 
Cytotoxicity 
Table 1 also shows CDS0 results in the two hepatoma 
cell lines. On day 4 the order of CDs0 was similar for 
HepG2 2.2.15 and HB 611, with the highest level of 
CDS0 for Lamivudine and lowest for Ara-AMP 
Comparing day 4 with day 12, lower levels (7-100 
fold) of CD50 were observed on day 12 for Lamivudine, 
PMEA, ddC and DHPG, but not for Ara-AMP 
The most dramatic change was noticed for ddC in 
HepG2 2.2.15 cells. In contrast to the results on day 4, 
the level of CD50 on day 12 suggests that the antiviral 
activity on day 12 may be strongly influenced by cyto- 
toxicity. This change steeply affected the therapeutic 
index of the drug (Table 1). 
Short treatment with PMEA and Lamivudine 
Fig. 1 illustrates that for PMEA and Lamivudine the 
concentration ranges of inhibitory activity and cyto- 
toxicity are clearly separated. These two agents were 
studied for post-exposure inhibitory properties after 
short-term exposure in HepG2 2.2.15 cells. HepG2 
2.2.15 cells were chosen for their favourable growth 
characteristics and higher virus yields compared to HB 
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Fig. I. Decrease of extracelhdar HBV-DNA in HepG2 
2.2.15 cells (I_ Lamivudine; + PMEA) and increase of 
cytotoxicity (-+R- Lamivudine; t_ PMEA) with increas- 
ing concentrations of antiviral agent. HBV-DNA was ex- 
tractedfrom culture medium on day 12 after 9 days of ex- 
posure of the cells to the drug. Cytotoxicity was measured 
on day 4 by [3H-methylJ dThd incorporation and measured 
after 24 h of incubation. 
611 cells. Extracellular HBV-DNA was evaluated on 
day 12. 
After 3 days of exposure to PMEA and Lamivudine, 
the IDso was 30 ,YM and 3.3 PM, respectively, com- 
pared to 1.2 and 0.02 PM, after 9 days of exposure. In 
the l-day exposure experiment PMEA and Lamivu- 
dine had IDSo’s of >lOO and 10 PM, respectively 
Discussion 
This is the first report on simultaneous investigation of 
antiviral agents in the two HBV-transfected hepatoma 
cell lines HepG2 2.2.15 and HB 611. The HBV inhibi- 
tory and cytotoxic effects of the agents under study 
were very similar for the two hepatoma cell lines after 
continuous exposure for 9 days. The order of effective- 
ness based on inhibition of extracellular HBV-DNA 
for both HepG2. 2.2.15 and HB 611 cell cultures was 
Lamivudine, PMEA, ddC, Ara-AMP DHPG and 
IFN-a. 
For comparison, in the literature IDso’s for Ara- 
AMP using HepG2 2.2.15 cells were reported as 36 PM 
for Ara-AMP (lo), 0.05 PM (12, 13) and 0.006 PM 
(14) for Sddc and 1.6 ,uM (15) and 3.6 PM (16) for 
ddC. 
PMEA (10 PM) inhibited HBV-DNA by 33% in 
HepG2 2.2.15 cells (10) and in HB 611 cells and IDso 
of 0.18 PM was reported (16). IFN-a inhibited HBV- 
DNA by 45% at a concentration of 10 000 IU/ml in 
HepG2 2.2.15 cells (17) and by 50% at 400 III/ml in 
HB 611 cells (15). 
DHPG was never assayed in HepG2 2.2.15 and HB 
611 cells. 
In most studies on HBV inhibitory agents, cytotox- 
icity in cell culture systems was measured in lympho- 
blastoid or hepatoma cell cultures early after plating 
of the cells. At that time cellular DNA synthesis is ex- 
pected to be highest. 
Antiviral activity, measured as inhibition of the level 
of HBV-DNA under continuous exposure to the drug 
is, in fact, because of the need to change the culture 
medium every 3 days, determined at the end of the 
treatment period. Therefore, we included in our study 
cytotoxicity measurements on day 12 in addition to the 
usual measurement of cytotoxicity at the start of treat- 
ment (day 4). For both cell lines we observed an in- 
crease in cytotoxicity for Lamivudine, PMEA, ddC 
and DHPG after prolonged drug treatment. The in- 
crease in cytotoxicity as measured by [3H-methyl] dThd 
incorporation was confirmed by cell death in dye fixing 
experiments (results not shown). 
The most dramatic change in CD50 upon time of 
evaluation was measured for ddC in HepG2 2.2.15 
cells. An unfavourable cytotoxic aspect of ddC was 
also apparent in inhibitory measurements of mitochon- 
drial DNA (12,13). In clinical trials peripheral neuro- 
pathy was observed at all doses (18-20). Our experi- 
ments suggest hat the elevated cytotoxicity of ddC on 
day 12 may result in an overestimation of the inhibi- 
tory effect on the level of HBV-DNA and a too favour- 
able therapeutic index for this drug. 
Reduction of HBsAg concomitant with HBVDNA 
in the culture medium could not be explained by ac- 
cumulation within a subcellular fraction, since with in- 
creasing drug concentration both intra-, and extra- 
cellular levels of HBV-DNA decreased quite similarly. 
Compared to the other agents in our study, Lamivu- 
dine is the most vigorous antiviral agent, with low 
toxicity on day 4 as well as day 12. Our in vitro findings 
with Lamivudine in these two cell lines were confirmed 
in pilot studies with Lamivudine in chronic hepatitis B 
patients (21). Furthermore, the outcome of our short 
exposure experiments are of interest for intermittent 
administration of antiviral drugs to reduce or avoid 
delayed toxic effects in man. 
In summary, with the limited number of agents in 
this study we conclude that HepG2 2.2.15 cells are 
more suitable than HB 611 because of higher virus 
yields and better culturing characteristics, with a simi- 
lar inhibitory effect on Dane particle secretion. 
The high yields of HBV from the HepG2 2.2.15 cells 
made it possible to use a 24-well tissue culture system 
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(results not shown) and to perform direct analysis of 
extra-cellular HBV-DNA in cell-culture medium with- 
out PEG concentration and DNA extraction or PCR 
capturing (22). 
Measuring cytotoxicity at the end of the incubation 
period may have a further discriminatory effect on the 
calculated and often overestimated therapeutic index. 
The severe toxicity observed in the FIAU study stresses 
once more the need for sensitive laboratory methods 
to predict toxic effects in man. Cell culture systems like 
HBV-producing hepatoma cell lines may be helpful in 
exploring this area. 
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